Ads
related to: ahrq 30 day readmission guidelines cancer drug information search- Request Representative
Fill Out A Brief Form To Request
Assistance From A Representative.
- Recommended Dosing
Determine The Appropriate Dosing
For A Patient On IMFINZI.
- Clinical Study Results
View Clinical Study Results
& Efficacy Info For IMFINZI.
- Safety Information
Learn About Safety & Efficacy
Information For IMFINZI.
- Request Representative
cancer.osu.edu has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
HCUP databases have been used in various studies on a number of topics, such as breast cancer, depression, and multimorbidity, incidence and cost of injuries, role of socioeconomic status in patients leaving against medical advice, multiple chronic conditions and disparities in readmissions, and hospitalization costs for cystic fibrosis.
Melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction (GEJ) cancer.
CMS defines a hospital readmission as "an admission to an acute care hospital within 30 days of discharge from the same or another acute care hospital. [1]" It uses an "all-cause" definition, meaning that the cause of the readmission does not need to be related to the cause of the initial hospitalization.
AHRQ headquarters at 5600 Fishers Lane in Rockville, Maryland. The 2015 budget for AHRQ was US$440 million, [8] $24 million less than FY 2014. The budget includes $334 million in Public Health Service (PHS) Evaluation Funds, a decrease of $30 million from FY 2014, and $106 million from the Patient-Centered Outcomes Research Trust Fund, an ...
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
Cancer cells can also cause defects in the cellular pathways of apoptosis (programmed cell death). As most chemotherapy drugs kill cancer cells in this manner, defective apoptosis allows survival of these cells, making them resistant. Many chemotherapy drugs also cause DNA damage, which can be repaired by enzymes in the cell that carry out DNA ...
Treatment of adults with limited stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT) [2] Elafibranor Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA ...
Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers.The editor-in-chief is Ruiwen Zhang (UH Drug Discovery Institute). The journal covers research on contemporary molecular drug targets involved in cancer, including medicinal chemistry, pharmacology, molecular biology, genomics, and biochemistry.